Nanoarchitectonics of PLGA based polymeric nanoparticles with oseltamivir phosphate for lung cancer therapy: In vitro-in vivo evaluation

2021 ◽  
pp. 102996
Author(s):  
Gülsel Yurtdaş-Kırımlıoğlu ◽  
Şennur Görgülü ◽  
Kadri Güleç ◽  
Hülya Tuba Kıyan
Keyword(s):  
Lung Cancer ◽  
Cancer Therapy ◽  
Polymeric Nanoparticles ◽  
In Vivo Evaluation ◽  
Lung Cancer Therapy ◽  
Oseltamivir Phosphate

scholarly journals Cancer Cell Membrane Decorated Silica Nanoparticle Loaded with miR495 and Doxorubicin to Overcome Drug Resistance for Effective Lung Cancer Therapy

2019 ◽  
Vol 14 (1) ◽  
Author(s):  
Jinyuan He ◽  
Chulian Gong ◽  
Jie Qin ◽  
Mingan Li ◽  
Shaohong Huang
Keyword(s):  
Lung Cancer ◽  
Cancer Therapy ◽  
Cell Membrane ◽  
Cancer Cells ◽  
Cancer Cell ◽  
Silica Nanoparticle ◽  
Glycoprotein P ◽  
Lung Cancer Therapy

Abstract Current cancer therapy usually succumbs to many extracellular and intracellular barriers, among which untargeted distribution and multidrug resistance (MDR) are two important difficulties responsible for poor outcome of many drug delivery systems (DDS). Here, in our study, the dilemma was addressed by developing a cancer cell membrane (CCM)-coated silica (SLI) nanoparticles to co-deliver miR495 with doxorubicin (DOX) for effective therapy of lung cancer (CCM/SLI/R-D). The homologous CCM from MDR lung cancer cells (A549/DOX) was supposed to increase the tumor-homing property of the DDS to bypass the extracellular barriers. Moreover, the MDR of cancer cells were conquered through downregulation of P-glycoprotein (P-gp) expression using miR495. It was proved that miR495 could significantly decrease the expression of P-gp which elevated intracellular drug accumulation in A549/DOX. The in vitro and in vivo results exhibited that CCM/SLI/R-D showed a greatly enhanced therapeutic effect on A549/DOX, which was superior than applying miR495 or DOX alone. The preferable effect of CCM/SLI/R-D on conquering the MDR in lung cancer provides a novel alternative for effective chemotherapy of MDR cancers.

Paclitaxel-loaded polymeric nanoparticles combined with chronomodulated chemotherapy on lung cancer: In vitro and in vivo evaluation

2017 ◽  
Vol 516 (1-2) ◽  
pp. 313-322 ◽  
Author(s):  
Jie Hu ◽  
Shaozhi Fu ◽  
Qiuxia Peng ◽  
YunWei Han ◽  
Jie Xie ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Polymeric Nanoparticles ◽  
In Vivo Evaluation

In vitro and in vivo evaluation of PEGylated nanoparticles of bendamustine for treatment of lung cancer

2015 ◽  
Vol 44 (6) ◽  
pp. 1491-1497 ◽  
Author(s):  
Pooja Dubey ◽  
Bina Gidwani ◽  
Ravindra Pandey ◽  
Shiv Shankar Shukla
Keyword(s):  
Lung Cancer ◽  
In Vivo Evaluation ◽  
Pegylated Nanoparticles

Novel folate-targeted docetaxel-loaded nanoparticles for tumour targeting: in vitro and in vivo evaluation

RSC Advances ◽  
2016 ◽  
Vol 6 (69) ◽  
pp. 64306-64314 ◽  
Author(s):  
M. H. Han ◽  
Z. T. Li ◽  
D. D. Bi ◽  
Y. F. Guo ◽  
H. X. Kuang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Folic Acid ◽  
Cancer Therapy ◽  
Targeted Delivery ◽  
Tumour Targeting ◽  
Breast Cancer Therapy ◽  
In Vivo Evaluation ◽  
Targeted Delivery System

Cholesterol-PEG1000-FA (folic acid) was synthesized as a stabilizer to encapsulate DTX, for the construction of a promising targeted delivery system for breast cancer therapy.

In vivo biological evaluation of polysaccharide-based nanocarriers targeting CD44 for lung cancer therapy

2014 ◽  
Vol 31 (7) ◽  
pp. 656-657
Author(s):  
V. Jeannot ◽  
S. Mazzaferro ◽  
J. Lavaud ◽  
V. Josserand ◽  
M. Guidetti ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Therapy ◽  
Biological Evaluation ◽  
Lung Cancer Therapy
Sign in / Sign up

Export Citation Format

Share Document